{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:19:52Z","timestamp":1784297992760,"version":"3.55.0"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0214305","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T17:41:36Z","timestamp":1553190096000},"page":"e0214305","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-7069","authenticated-orcid":true,"given":"Birgit","family":"Spiess","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Rinaldetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Galuschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Kossak-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Wuchter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Tarnopolscaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astghik","family":"Voskanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fabarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Sau\u00dfele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Seifarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"C Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"ref2","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008","volume":"29","author":"M Bjorkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-Adapted Imatinib 800 mg\/d Versus 400 mg\/d Versus 400 mg\/d Plus Interferon-alpha in Newly Diagnosed Chronic Myeloid Leukemia.","volume":"29","author":"R Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"R Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"F Castagnetti","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10\u2013year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"R Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"S Saussele","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"TP Hughes","year":"2016","journal-title":"Blood"},{"issue":"9","key":"ref9","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/cam4.801","article-title":"Deep molecular responses for treatment-free remission in chronic myeloid leukemia","volume":"5","author":"S Dulucq","year":"2016","journal-title":"Cancer medicine"},{"key":"ref10","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","author":"S Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"ref11","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1007\/s00277-015-2315-1","article-title":"Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization","volume":"94","author":"NC Cross","year":"2015","journal-title":"Ann Hematol"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"NCP Cross","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/sj.leu.2401566","article-title":"Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR","volume":"13","author":"M Emig","year":"1999","journal-title":"Leukemia"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.leu.2401811","article-title":"Detection and quantification of residual disease in chronic myelogenous leukemia","volume":"14","author":"A Hochhaus","year":"2000","journal-title":"Leukemia"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/leu.2014.217","article-title":"A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR","volume":"29","author":"H White","year":"2015","journal-title":"Leukemia"},{"issue":"18684859","key":"ref16","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"S Branford","year":"2008","journal-title":"Blood"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"MC M\u00fcller","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"T Hughes","year":"2006","journal-title":"Blood"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","article-title":"Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia","volume":"153","author":"L Foroni","year":"2011","journal-title":"Br J Haematol"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"e0196326","DOI":"10.1371\/journal.pone.0196326","article-title":"The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia","volume":"13","author":"B Spiess","year":"2018","journal-title":"PLoS One"},{"issue":"17943168","key":"ref21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.leu.2404983","article-title":"Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories","volume":"22","author":"MC M\u00fcller","year":"2008","journal-title":"Leukemia"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program","volume":"17","author":"J Gabert","year":"2003","journal-title":"Leukemia"},{"key":"ref23","article-title":"The quality toolbox","author":"NR Tague","year":"2004"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe against cancer program","volume":"17","author":"E Beillard","year":"2003","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bdq.2017.01.001","article-title":"Molecular techniques for the personalised management of patients with chronic myeloid leukaemia","volume":"11","author":"M Alikian","year":"2017","journal-title":"Biomolecular detection and quantification"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2353\/jmoldx.2006.040404","article-title":"Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts","volume":"8","author":"YL Wang","year":"2006","journal-title":"J Mol Diagn"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00277-013-1920-0","article-title":"A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms","volume":"93","author":"F Fantasia","year":"2014","journal-title":"Ann Hematol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0214305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:20:22Z","timestamp":1588965622000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0214305"}},"subtitle":[],"editor":[{"given":"Susan","family":"Branford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0214305","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]}}}